• SPX
  • $5,969.34
  • 0.35 %
  • $20.63
  • DJI
  • $44,296.51
  • 0.97 %
  • $426.16
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $19,003.65
  • 0.16 %
  • $31.23
Inovio Pharmaceuticals, Inc. (INO) Stock Price, News & Analysis

Inovio Pharmaceuticals, Inc. (INO) Stock Price, News & Analysis

Currency in USD Disclaimer

$4.08

$0.02

(0.49%)

Day's range
$4.04
Day's range
$4.21
50-day range
$3.85
Day's range
$7
  • Country: US
  • ISIN: US45773H4092
52 wk range
$3.85
Day's range
$14.75
  • CEO: Dr. Jacqueline E. Shea Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 0.74
  • Piotroski Score 1.00
  • Grade Outperform
  • Symbol (INO)
  • Company Inovio Pharmaceuticals, Inc.
  • Price $4.08
  • Changes Percentage (0.49%)
  • Change $0.02
  • Day Low $4.04
  • Day High $4.21
  • Year High $14.75

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

  • Last Earnings 09/21/2017
  • Ex-Dividend for 5/16 Dividend 09/28/2017
  • Dividend Payable 10/16/2017
  • Today N/A
  • Next Earnings (Estimated) 03/04/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $20.00
  • High Stock Price Target $40.00
  • Low Stock Price Target $8.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$5.51
  • Trailing P/E Ratio -1.74
  • Forward P/E Ratio -1.74
  • P/E Growth -1.74
  • Net Income $-135,117,352

Income Statement

Quarterly

Annual

Latest News of INO

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Inovio Pharmaceuticals, Inc. Frequently Asked Questions

  • What were the earnings of INO in the last quarter?

    In the last quarter Inovio Pharmaceuticals, Inc. earnings were on Thursday, November, 14th. The Inovio Pharmaceuticals, Inc. maker reported -$0.89 EPS for the quarter, beating analysts' consensus estimates of -$1.20 by $0.31.

  • What is the Inovio Pharmaceuticals, Inc. stock price today?

    Today's price of Inovio Pharmaceuticals, Inc. is $4.08 — it has increased by +0.49% in the past 24 hours. Watch Inovio Pharmaceuticals, Inc. stock price performance more closely on the chart.

  • Does Inovio Pharmaceuticals, Inc. release reports?

    Yes, you can track Inovio Pharmaceuticals, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Inovio Pharmaceuticals, Inc. stock forecast?

    Watch the Inovio Pharmaceuticals, Inc. chart and read a more detailed Inovio Pharmaceuticals, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Inovio Pharmaceuticals, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Inovio Pharmaceuticals, Inc. stock ticker.

  • How to buy Inovio Pharmaceuticals, Inc. stocks?

    Like other stocks, INO shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Inovio Pharmaceuticals, Inc.'s EBITDA?

    Inovio Pharmaceuticals, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Inovio Pharmaceuticals, Inc.’s financial statements.

  • What is the Inovio Pharmaceuticals, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -162.3987115539, which equates to approximately -16,239.87%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Inovio Pharmaceuticals, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Inovio Pharmaceuticals, Inc.'s financials relevant news, and technical analysis. Inovio Pharmaceuticals, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Inovio Pharmaceuticals, Inc. stock currently indicates a “sell” signal. For more insights, review Inovio Pharmaceuticals, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.